Osimertinib: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='99/999451/Cv/1'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='99/999451/Cv/1'> | ||
Osimertinib, sold under the brand name Tagrisso,<ref name="a4">[https://www.who.int/medicines/publications/druginformation/INN_List113.pdf "Proposed INN: List 113"] (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015</ref> is a medication used to treat non-small-cell lung carcinomas with specific mutations.<ref name="a5">PMID:26169963</ref><ref name="a6">PMID:26370354</ref> It is a third-generation [[epidermal growth factor receptor]] [[tyrosine kinase]] inhibitor. | Osimertinib, sold under the brand name Tagrisso,<ref name="a4">[https://www.who.int/medicines/publications/druginformation/INN_List113.pdf "Proposed INN: List 113"] (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015</ref> is a medication used to treat non-small-cell lung carcinomas with specific mutations.<ref name="a5">PMID:26169963</ref><ref name="a6">PMID:26370354</ref> It is a third-generation [[epidermal growth factor receptor]] [[tyrosine kinase]] inhibitor. See also [https://en.wikipedia.org/wiki/Osimertinib Osimertinib]. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 15:06, 10 October 2023
Osimertinib, sold under the brand name Tagrisso,[1] is a medication used to treat non-small-cell lung carcinomas with specific mutations.[2][3] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. See also Osimertinib.
|
| ||||||||||
ReferencesReferences
- ↑ "Proposed INN: List 113" (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015
- ↑ Ayeni D, Politi K, Goldberg SB. Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer. Clin Cancer Res. 2015 Sep 1;21(17):3818-20. PMID:26169963 doi:10.1158/1078-0432.CCR-15-1211
- ↑ Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015 Sep;16(9):e447-e459. PMID:26370354 doi:10.1016/S1470-2045(15)00246-6